Skip to main content

Table 2 Multivariate analysis of survival by lymph node ratio and pN stage

From: Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy

Characteristic LRFS OS
  HR (95% CI) p HR (95% CI) p
Age (y)     
 ≤ 35 vs. > 35 1.664 (1.082-2.558) 0.020*  
Menopausal status     
 Pre- vs. postmenopausal 1.623 (1.106-2.383) 0.105  
Tumor size     
 T3-4 vs. T1-2 1.636 (1.029-2.600) 0.037 1.392 (0.917-2.113) 0.121
ER status     
 Negative vs. positive 1.536 (1.095-2.155) 0.013* 1.054 (0.699-1.590) 0.802
PR status     
 Negative vs. positive 1.626 (1.148-2.302) 0.317 1.490 (1.040-2.136) 0.030*
HER-2-neu status     
 Positive vs. negative   1.208 (0.888-1.644) 0.228
Hormone therapy     
 None vs. yes 1.180 (0.731-1.904) 0.498 1.570(1.093-2.255) 0.015*
Lymph node ratio     
 < 0.20 1 (Reference)   1 (Reference)  
 0.21-0.65 1.886 (1.273-2.794) 0.002* 1.964 (1.387-2.782) <0.001*
 > 0.65 5.013 (3.191-7.877) <0.001* 7.381 (5.161-10.557) <0.001*
Number of positive lymph nodes     
 pN1 1 (Reference)    
 pN2 0.828 (0.476-1.442) 0.522 1.327 (0.808-2.179) 0.263
 pN3 0.894 (0.437-1.828) 0.907 1.654 (0.904-3.027) 0.103
  1. LRFS, Locoregional recurrence-free survival; OS, Overall survival; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, Human epithelial growth factor receptor family 2; HR, Hazard ratio; CI, Confidence interval.
  2. *p<0.05 indicates a significant difference.